Авторы

  • Бобоев К.Т.
  • Каримов Х.Я.
  • Мусашайхова Ш.М.
  • Мусашайхов Х.Т.

Ключевые слова:

мутация, генетический маркер NPM1, геморрагия, тромбоцитопения, бластные клетки.

Библиографические ссылки

Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367-1376.

Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;127:1551-1558.

Ma L, Li X, Zhang J, et al. [Acquired aplastic anemia developing myelodysplastic syndrome / acute myeloid leukemia: clinical analysis of nineteen patients and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2015;36:216-220.

Nguyen B, Williams AB, FLT3 activating mutations display differential sensitivity to multiple tyrosinekinase inhibitors. Oncotarget. 2017; 8(7): 10931–44.

Ommer C. Allogeneic FLT3 CAR T Cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. 2020.

Papaemmanuil E, Gerstung M, Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.

Rose D., Haferlach T., Schnittger S., et al. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31:11-17.

Sallman D.A., McLemore A.F., Aldrich A.L., Komrokji R.S., McGraw K.L., Dhawan A., Geyer S., Hou H.-A., Eksioglu E.A., Sullivan A., et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136:2812–2823. doi: 10.1182/blood.2020006 158.

Sanchez R, Ayala R, Alonso RA, Martinez MP, Ribera J, Garcia O, Sanchez-Pina J, Mercadal S, Montesinos P, Martino R, Barba P, et al. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Ann Hematol. 2017; 96(7):1069–1075.

Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019;12:1937–45.